Danazol
Danazol is an old hormone tablet, licensed for endometriosis, that can raise haemoglobin and platelets in myelofibrosis and bone marrow failure. It was the comparison treatment that momelotinib beat in the MOMENTUM trial.
Overview
Danazol is a synthetic androgen licensed since the 1970s for endometriosis, fibrocystic breast disease and hereditary angioedema. In haematology it is used off-label for the anaemia of myelofibrosis and myelodysplastic syndromes and for immune and aplastic cytopenias, where about a third of patients improve; it also lengthens telomeres in telomere-biology disorders.
In the phase 3 MOMENTUM trial in symptomatic, anaemic myelofibrosis previously treated with a JAK inhibitor, danazol was the active comparator: 25 percent of patients on momelotinib had their symptom score halve against 9 percent on danazol, and more became transfusion independent. Liver toxicity, virilisation and thrombosis limit its use. The primary myelofibrosis page names it among the treatments for anaemia.
A weak androgen derived from ethisterone that stimulates erythropoiesis and thrombopoiesis, in part by raising telomerase activity in haematopoietic cells, and suppresses gonadotropins.
1.Danazol acts on its target, the hormone receptor or the enzyme that makes the hormone.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Danazol" OR ABSTRACT:"Danazol" OR TITLE:"Danocrine" OR ABSTRACT:"Danocrine" OR TITLE:"Danol" OR ABSTRACT:"Danol") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Danazol, not a curated reading list.
Similar pages
not linked directly; found by shared links- TermPost-PV myelofibrosis (spent phase)
Shares Momelotinib, Primary myelofibrosis.
- Key paperMOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor
Shares Momelotinib, Primary myelofibrosis.
- TermDIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)
Shares Momelotinib, Primary myelofibrosis.
- Key paperCOMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis
Shares Momelotinib, Primary myelofibrosis.
- TargetJAK2
Shares Momelotinib, Primary myelofibrosis.